Staidson Beijing Biopharma (300204) — Capital Reinvestment Ratio
Staidson Beijing Biopharma (300204) has a Capital Reinvestment Ratio of 1.01x as of March 2020, meaning it reinvests 1% of its operating cash flow (CN¥26.92 Million) in capital expenditures (CN¥27.14 Million). See 300204 net asset quality index to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Staidson Beijing Biopharma Capital Reinvestment Ratio (2007–2019)
This chart tracks Staidson Beijing Biopharma's Capital Reinvestment Ratio across 13 annual periods. Check total reinvestment intensity of Staidson Beijing Biopharma to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Staidson Beijing Biopharma (2007–2019)
Year-by-year Capital Reinvestment Ratio for Staidson Beijing Biopharma from 2007 to 2019. For live market cap and broader valuation context, see 300204 stock market capitalisation.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2019 | 1.35x | CN¥44.34 Million | CN¥59.91 Million | ▲ +133.6% |
| 2018 | 0.58x | CN¥165.08 Million | CN¥95.46 Million | ▲ +239.9% |
| 2017 | 0.17x | CN¥273.64 Million | CN¥46.55 Million | ▲ +36.7% |
| 2016 | 0.12x | CN¥212.55 Million | CN¥26.45 Million | ▲ +20.0% |
| 2015 | 0.10x | CN¥231.01 Million | CN¥23.95 Million | ▲ +48.2% |
| 2014 | 0.07x | CN¥206.85 Million | CN¥14.47 Million | ▼ -66.2% |
| 2013 | 0.21x | CN¥111.36 Million | CN¥23.02 Million | ▼ -68.3% |
| 2012 | 0.65x | CN¥90.19 Million | CN¥58.88 Million | ▼ -32.7% |
| 2011 | 0.97x | CN¥87.01 Million | CN¥84.35 Million | ▼ -24.7% |
| 2010 | 1.29x | CN¥63.91 Million | CN¥82.25 Million | ▲ +313.3% |
| 2009 | 0.31x | CN¥42.37 Million | CN¥13.19 Million | ▼ -69.9% |
| 2008 | 1.04x | CN¥16.23 Million | CN¥16.81 Million | ▲ +1535.6% |
| 2007 | 0.06x | CN¥5.41 Million | CN¥342.40K | — |